Last reviewed · How we verify
adrenaline, promethazine, hydrocortisone
This combination uses adrenaline to stimulate adrenergic receptors for rapid cardiovascular support, promethazine to block histamine and provide sedation, and hydrocortisone to suppress inflammation and immune response.
This combination uses adrenaline to stimulate adrenergic receptors for rapid cardiovascular support, promethazine to block histamine and provide sedation, and hydrocortisone to suppress inflammation and immune response. Used for Anaphylaxis (acute allergic reaction), Severe allergic reactions with cardiovascular compromise, Acute inflammatory conditions with hemodynamic instability.
At a glance
| Generic name | adrenaline, promethazine, hydrocortisone |
|---|---|
| Sponsor | University of Kelaniya |
| Drug class | Combination therapy: sympathomimetic, antihistamine, corticosteroid |
| Target | Adrenergic receptors (α1, α2, β1, β2); H1 histamine receptor; glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Emergency Medicine / Allergy / Immunology |
| Phase | FDA-approved |
Mechanism of action
Adrenaline acts as a sympathomimetic agent, increasing heart rate and blood pressure through α and β-adrenergic receptor activation. Promethazine is a first-generation antihistamine that blocks H1 receptors and has anticholinergic properties, reducing histamine-mediated reactions and providing sedation. Hydrocortisone is a glucocorticoid that suppresses inflammatory and immune responses by inhibiting phospholipase A2 and reducing cytokine production.
Approved indications
- Anaphylaxis (acute allergic reaction)
- Severe allergic reactions with cardiovascular compromise
- Acute inflammatory conditions with hemodynamic instability
Common side effects
- Tachycardia
- Hypertension
- Tremor
- Anxiety
- Drowsiness (from promethazine)
- Hyperglycemia (from hydrocortisone)
Key clinical trials
- Siplizumab for Sickle Cell Disease Transplant (PHASE1, PHASE2)
- Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia (PHASE2)
- Intermediate-size Expanded Access Program (EAP), Mesenchymal Stromal Cells (MSC) for Multisystem Inflammatory Syndrome in Children (MIS-C) Associated With Coronavirus Disease (COVID-19)
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia (PHASE3)
- Allogeneic Transplantation From Related Haploidentical Donors (PHASE2)
- Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT (PHASE2)
- Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD (PHASE2)
- Phase 2 Study of Autologous Followed by Nonmyeloablative Allogeneic Transplantation Using TLI & ATG (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: